Bossart, Simon; Seyed Jafari, S Morteza; Heidemeyer, Kristine; Yan, Kexiang; Feldmeyer, Laurence; Borradori, Luca; Yawalkar, Nikhil (2023). Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome. Frontiers in medicine, 10(1050230), p. 1050230. Frontiers 10.3389/fmed.2023.1050230
|
Text
fmed-10-1050230.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (752kB) | Preview |
Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Bossart, Simon, Jafari, Morteza, Heidemeyer, Kristine, Feldmeyer, Laurence, Borradori, Luca, Yawalkar, Nikhil |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2296-858X |
Publisher: |
Frontiers |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
04 Apr 2023 10:48 |
Last Modified: |
09 Apr 2023 02:17 |
Publisher DOI: |
10.3389/fmed.2023.1050230 |
PubMed ID: |
37007766 |
Uncontrolled Keywords: |
Canakinumab Schnitzler syndrome autoinflammatory disorders immunohistochemical neutrophilic inflammation |
BORIS DOI: |
10.48350/181482 |
URI: |
https://boris.unibe.ch/id/eprint/181482 |
Actions (login required)
 |
Edit item |